Alvotech (ALVO) EBITDA Margin (2022 - 2026)
Alvotech's (ALVO) quarterly EBITDA Margin came in at 134.08% in Q2 2026, down 12485.0% on a YoY basis from N/an in Q2 2025, and down 809.33% quarter-over-quarter from 18.9% in Q1 2026.
Powered by 
Analysis
Alvotech (ALVO) EBITDA Margin (2022 - 2026) Analysis & Trends
Alvotech (ALVO) has reported EBITDA Margin for 5 consecutive years, with 134.08% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBITDA Margin fell 12485.0% year-over-year to 134.08%; the trailing twelve-month figure through Jun 2026 stood at 85.35% (down 12450.0% YoY), and the FY2025 full-year result was 28.31%, up 13333.0% from the prior year.
- EBITDA Margin declined to 134.08% in Q2 2026 per ALVO's latest filing, from 18.9% in the prior quarter.
- Across five years, EBITDA Margin topped out at 2170.0% in Q2 2023 and bottomed at 8810.83% in Q4 2022.
- Historically, EBITDA Margin has averaged 975.48% across 5 years, with a median of 201.1% in 2026.
- The sharpest annual moves came in 2023 and 2024: EBITDA Margin jumped 693317 bps in 2023, then slumped 243813 bps in 2024.
- Over 5 years, EBITDA Margin stood at 8810.83% in 2022, then soared by 79 bps to 1877.67% in 2023, then jumped by 85 bps to 291.02% in 2024, then surged by 112 bps to 36.19% in 2025, then plunged by 470 bps to 134.08% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 134.08%, 18.9%, and 36.19% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.58 Bn | 38.93 Bn | 2.15 Bn | -5.58% |
| 2 | Viatris | 19.17 Bn | 18.28 Bn | 1.46 Bn | 0.17% |
| 3 | Dr Reddys Laboratories | 9.87 Bn | 9.70 Bn | 396.53 Mn | 4.69% |
| 4 | Amneal Pharmaceuticals | 5.48 Bn | 5.36 Bn | 334.51 Mn | 16.30% |
| 5 | Bausch Health Companies | 2.35 Bn | 507.63 Mn | 2.10 Bn | 25.95% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | -134.08% |
| 7 | Ani Pharmaceuticals | 1.48 Bn | 1.12 Bn | 165.89 Mn | 15.21% |
| 8 | Amphastar Pharmaceuticals | 995.96 Mn | 705.83 Mn | 93.47 Mn | 21.60% |
| 9 | Fennec Pharmaceuticals | 401.41 Mn | 360.16 Mn | 17.15 Mn | 9.72% |
| 10 | RedHill Biopharma | 176.59 Mn | 176.59 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -134.08% |
| Mar 31, 2026 | 18.90% |
| Dec 31, 2025 | 36.19% |
| Sep 30, 2025 | -929.24% |
| Jun 30, 2025 | -9.22% |
| Mar 31, 2025 | 75.37% |
| Dec 31, 2024 | -291.02% |
| Sep 30, 2024 | 399.30% |
| Jun 30, 2024 | -268.13% |
| Mar 31, 2024 | -389.53% |
| Dec 31, 2023 | -1,877.67% |
| Aug 31, 2023 | -832.49% |
| Jun 30, 2023 | 2,170.00% |
| Dec 31, 2022 | -8,810.83% |
| Aug 31, 2022 | -5,177.62% |
| Jun 30, 2022 | 412.31% |